Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
tirzepatide cardiovascular outcomes trial results july 2025 In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but offered no additional benefit over semaglutide. #ESCCongress TP-Active Subscription:3 months Consumer Option - MHBP
Consumer Option - MHBP Federal Health Plans
Regular monitoring also catches any rare thyroid-related side effects early, though tirzepatide itself does not trigger hypothyroidism or thyroid inflammation
TP-Active
Subscription:3 months
Medically supervised weight loss with GLP-1 options, personalized prescriptions, and expert 1:1 counseling
)
)
